 Connection
Arnon Haran to Humans
This is a "connection" page, showing publications Arnon Haran has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.093 |
|
|
|
-
Haran A, Even-Zohar NG, Haran M, Lebel E, Aumann S, Shaulov A, Gatt M, Nachmias B. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):187-193.e1.
Score: 0.020
-
Haran A, Temper V, Assous M, Bergel M, Chahanian N, Elinav H, Korem M. False-positive galactomannan antigen testing in pulmonary nocardiosis. Med Mycol. 2021 Feb 04; 59(2):206-209.
Score: 0.017
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
Score: 0.006
-
Gross Even-Zohar N, Aumann S, Shaulov A, Haran A, Nachmias B, Lebel E, Lehmann-Werman R, Gatt ME. First case report of talquetamab use in AL amyloidosis. Leuk Lymphoma. 2025 Dec; 66(14):2618-2623.
Score: 0.006
-
Nachmias B, Haran A, Yisraeli Salman M, Stein EM. Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights. Br J Haematol. 2025 Oct; 207(4):1192-1212.
Score: 0.006
-
Gross Even Zohar N, Oanunu U, Gross Even-Zohar N, Aumann S, Vainstein V, Gural A, Gatt ME, Haran A, Nachmias B. Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia. Acta Haematol. 2025; 148(6):664-674.
Score: 0.005
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
Score: 0.005
-
Nachmias B, Aumann S, Haran A, Schimmer AD. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights. Br J Haematol. 2024 Apr; 204(4):1146-1158.
Score: 0.005
-
Burstein R, Aviv A, Even-Zohar NG, Nachmias B, Haran A, Braun M, Rottenberg Y, Shaulov A. Comparing end-of-life care of hematologic malignancy versus solid tumor patients in a tertiary care center. Eur J Haematol. 2023 Oct; 111(4):528-535.
Score: 0.005
-
Canaani J, Frisch A, Pollyea DA, Schwartz M, Aumann S, Ganzel C, Haran A, Even-Zohar NG, Shaulov A, Vainstein V, Moshe Y, Ofran Y, Wolach O, Nachmias B. Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. Eur J Haematol. 2023 Sep; 111(3):365-372.
Score: 0.005
-
Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2022 Sep 19; 23(18).
Score: 0.005
-
Hefetz L, Ben-Haroush Schyr R, Bergel M, Arad Y, Kleiman D, Israeli H, Samuel I, Azulai S, Haran A, Levy Y, Sender D, Rottenstreich A, Ben-Zvi D. Maternal antagonism of Glp1 reverses the adverse outcomes of sleeve gastrectomy on mouse offspring. JCI Insight. 2022 04 08; 7(7).
Score: 0.004
-
Abu-Gazala S, Bergel M, Arad Y, Hefetz L, Azulai S, Baker A, Haran A, Israeli H, Kleiman D, Samuel I, Tsubary U, Permyakova A, Tam J, Ben-Haroush Schyr R, Ben-Zvi D. Generation and characterization of a mouse model for one anastomosis gastric bypass surgery. Am J Physiol Endocrinol Metab. 2022 05 01; 322(5):E414-E424.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|